Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: A prospective followup study

Carlo Salvarani, Fabrizio Cantini, Laura Niccoli, Pierluigi Macchioni, Dario Consonni, Gianluigi Bajocchi, Marco Vinceti, Maria Grazia Catanoso, Lia Pulsatelli, Riccardo Meliconi, Luigi Boiardi

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Objective. To determine laboratory parameters that may be useful in identifying polymyalgia rheumatica (PMR) patients who require long-term corticosteroid therapy. Methods. A prospective followup study of 94 consecutive untreated patients with PMR were assessed for relapse/recurrence for a mean of 39 months. This cohort represented all the patients diagnosed over a 4-year period in 2 Italian secondary referral centers. Patients were monitored for clinical signs and symptoms, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and serum interleukin-6 (IL-6). IL-6 levels were also measured in 43 controls matched to the patients for age and sex. Results. The ESR was elevated in 91.5% of the patients prior to therapy initiation, as were CRP in 98.9% and serum IL-6 in 92.6%. Forty-seven (50.0%) patients had at least 1 relapse/recurrence during the followup period and 24 (25.5%) had at least 2. After 4 weeks of prednisone therapy, ESR was elevated in 13.2% patients, CRP in 41.9%, and serum IL-6 in 37.2%. IL-6 levels remained persistently elevated in 9.9% and CRP in 8.7% of patients during the first year of followup, whereas no patient had persistently elevated ESR. Persistently elevated CRP and IL-6 levels were significantly associated with an increased risk of relapse/recurrence. In particular, patients with persistently elevated levels of IL-6 during the first year of therapy had the highest relative risk. Conclusion. Despite the control of clinical symptoms, corticosteroids do not adequately control the inflammatory process in a subset of patients with PMR who have persistently elevated levels of CRP and IL-6 and who have a higher risk of relapsing.

Original languageEnglish
Pages (from-to)33-38
Number of pages6
JournalArthritis Care and Research
Volume53
Issue number1
DOIs
Publication statusPublished - Feb 15 2005

Fingerprint

Polymyalgia Rheumatica
Acute-Phase Proteins
Prospective Studies
Recurrence
Interleukin-6
C-Reactive Protein
Blood Sedimentation
Adrenal Cortex Hormones
Secondary Care Centers
Serum
Therapeutics
Prednisone
Signs and Symptoms

Keywords

  • C-reactive protein
  • Erythrocyte sedimentation rate
  • Interleukin-6
  • Polymyalgia rheumatica
  • Recurrence
  • Relapse

ASJC Scopus subject areas

  • Rheumatology

Cite this

Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica : A prospective followup study. / Salvarani, Carlo; Cantini, Fabrizio; Niccoli, Laura; Macchioni, Pierluigi; Consonni, Dario; Bajocchi, Gianluigi; Vinceti, Marco; Catanoso, Maria Grazia; Pulsatelli, Lia; Meliconi, Riccardo; Boiardi, Luigi.

In: Arthritis Care and Research, Vol. 53, No. 1, 15.02.2005, p. 33-38.

Research output: Contribution to journalArticle

Salvarani, Carlo ; Cantini, Fabrizio ; Niccoli, Laura ; Macchioni, Pierluigi ; Consonni, Dario ; Bajocchi, Gianluigi ; Vinceti, Marco ; Catanoso, Maria Grazia ; Pulsatelli, Lia ; Meliconi, Riccardo ; Boiardi, Luigi. / Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica : A prospective followup study. In: Arthritis Care and Research. 2005 ; Vol. 53, No. 1. pp. 33-38.
@article{b167aa2462b64a7ba2ef7449479d2692,
title = "Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: A prospective followup study",
abstract = "Objective. To determine laboratory parameters that may be useful in identifying polymyalgia rheumatica (PMR) patients who require long-term corticosteroid therapy. Methods. A prospective followup study of 94 consecutive untreated patients with PMR were assessed for relapse/recurrence for a mean of 39 months. This cohort represented all the patients diagnosed over a 4-year period in 2 Italian secondary referral centers. Patients were monitored for clinical signs and symptoms, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and serum interleukin-6 (IL-6). IL-6 levels were also measured in 43 controls matched to the patients for age and sex. Results. The ESR was elevated in 91.5{\%} of the patients prior to therapy initiation, as were CRP in 98.9{\%} and serum IL-6 in 92.6{\%}. Forty-seven (50.0{\%}) patients had at least 1 relapse/recurrence during the followup period and 24 (25.5{\%}) had at least 2. After 4 weeks of prednisone therapy, ESR was elevated in 13.2{\%} patients, CRP in 41.9{\%}, and serum IL-6 in 37.2{\%}. IL-6 levels remained persistently elevated in 9.9{\%} and CRP in 8.7{\%} of patients during the first year of followup, whereas no patient had persistently elevated ESR. Persistently elevated CRP and IL-6 levels were significantly associated with an increased risk of relapse/recurrence. In particular, patients with persistently elevated levels of IL-6 during the first year of therapy had the highest relative risk. Conclusion. Despite the control of clinical symptoms, corticosteroids do not adequately control the inflammatory process in a subset of patients with PMR who have persistently elevated levels of CRP and IL-6 and who have a higher risk of relapsing.",
keywords = "C-reactive protein, Erythrocyte sedimentation rate, Interleukin-6, Polymyalgia rheumatica, Recurrence, Relapse",
author = "Carlo Salvarani and Fabrizio Cantini and Laura Niccoli and Pierluigi Macchioni and Dario Consonni and Gianluigi Bajocchi and Marco Vinceti and Catanoso, {Maria Grazia} and Lia Pulsatelli and Riccardo Meliconi and Luigi Boiardi",
year = "2005",
month = "2",
day = "15",
doi = "10.1002/art.20901",
language = "English",
volume = "53",
pages = "33--38",
journal = "Arthritis care and research : the official journal of the Arthritis Health Professions Association",
issn = "0893-7524",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica

T2 - A prospective followup study

AU - Salvarani, Carlo

AU - Cantini, Fabrizio

AU - Niccoli, Laura

AU - Macchioni, Pierluigi

AU - Consonni, Dario

AU - Bajocchi, Gianluigi

AU - Vinceti, Marco

AU - Catanoso, Maria Grazia

AU - Pulsatelli, Lia

AU - Meliconi, Riccardo

AU - Boiardi, Luigi

PY - 2005/2/15

Y1 - 2005/2/15

N2 - Objective. To determine laboratory parameters that may be useful in identifying polymyalgia rheumatica (PMR) patients who require long-term corticosteroid therapy. Methods. A prospective followup study of 94 consecutive untreated patients with PMR were assessed for relapse/recurrence for a mean of 39 months. This cohort represented all the patients diagnosed over a 4-year period in 2 Italian secondary referral centers. Patients were monitored for clinical signs and symptoms, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and serum interleukin-6 (IL-6). IL-6 levels were also measured in 43 controls matched to the patients for age and sex. Results. The ESR was elevated in 91.5% of the patients prior to therapy initiation, as were CRP in 98.9% and serum IL-6 in 92.6%. Forty-seven (50.0%) patients had at least 1 relapse/recurrence during the followup period and 24 (25.5%) had at least 2. After 4 weeks of prednisone therapy, ESR was elevated in 13.2% patients, CRP in 41.9%, and serum IL-6 in 37.2%. IL-6 levels remained persistently elevated in 9.9% and CRP in 8.7% of patients during the first year of followup, whereas no patient had persistently elevated ESR. Persistently elevated CRP and IL-6 levels were significantly associated with an increased risk of relapse/recurrence. In particular, patients with persistently elevated levels of IL-6 during the first year of therapy had the highest relative risk. Conclusion. Despite the control of clinical symptoms, corticosteroids do not adequately control the inflammatory process in a subset of patients with PMR who have persistently elevated levels of CRP and IL-6 and who have a higher risk of relapsing.

AB - Objective. To determine laboratory parameters that may be useful in identifying polymyalgia rheumatica (PMR) patients who require long-term corticosteroid therapy. Methods. A prospective followup study of 94 consecutive untreated patients with PMR were assessed for relapse/recurrence for a mean of 39 months. This cohort represented all the patients diagnosed over a 4-year period in 2 Italian secondary referral centers. Patients were monitored for clinical signs and symptoms, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and serum interleukin-6 (IL-6). IL-6 levels were also measured in 43 controls matched to the patients for age and sex. Results. The ESR was elevated in 91.5% of the patients prior to therapy initiation, as were CRP in 98.9% and serum IL-6 in 92.6%. Forty-seven (50.0%) patients had at least 1 relapse/recurrence during the followup period and 24 (25.5%) had at least 2. After 4 weeks of prednisone therapy, ESR was elevated in 13.2% patients, CRP in 41.9%, and serum IL-6 in 37.2%. IL-6 levels remained persistently elevated in 9.9% and CRP in 8.7% of patients during the first year of followup, whereas no patient had persistently elevated ESR. Persistently elevated CRP and IL-6 levels were significantly associated with an increased risk of relapse/recurrence. In particular, patients with persistently elevated levels of IL-6 during the first year of therapy had the highest relative risk. Conclusion. Despite the control of clinical symptoms, corticosteroids do not adequately control the inflammatory process in a subset of patients with PMR who have persistently elevated levels of CRP and IL-6 and who have a higher risk of relapsing.

KW - C-reactive protein

KW - Erythrocyte sedimentation rate

KW - Interleukin-6

KW - Polymyalgia rheumatica

KW - Recurrence

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=13444294248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13444294248&partnerID=8YFLogxK

U2 - 10.1002/art.20901

DO - 10.1002/art.20901

M3 - Article

C2 - 15696567

AN - SCOPUS:13444294248

VL - 53

SP - 33

EP - 38

JO - Arthritis care and research : the official journal of the Arthritis Health Professions Association

JF - Arthritis care and research : the official journal of the Arthritis Health Professions Association

SN - 0893-7524

IS - 1

ER -